The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
Beckman Coulter has expanded the anemia menu of the Access family of immunoassay systems to include a test for EPO. This aids in the diagnosis of polycythemia or overproduction of erythrocytes, and helps clinicians to differentiate polycythemia caused by conditions such as decreased oxygen in the tissues from neoplastic bone marrow disorders.
Biosite is collaborating with Oxford Genome for the evaluation of blood protein-based disease markers for the early identification of colorectal cancer patients that have relapsed.
Cell Biosciences introduced the Firefly 3000 automated blotless immunoassay workstation for quantitative measurement of cell signaling and protein expression. The Firefly is a 96 capillary automated electrophoresis system that is optimized for isoelectric focusing.
DexCom, Inc. received FDA clearance to market its STS Continuous Glucose Monitoring System. The DexCom STS consists of a tiny wire-like sensor that is inserted by the patient just under the skin. The sensor continuously measures glucose levels which are transmitted wirelessly to the cell phone-like STS Receiver. With the push of a button, the handheld Receiver conveniently provides the patient with real-time glucose measurements and trends, as well as providing alerts to warn of high and low glucose levels.
Haemonetics Corporation launched the Cymbal system blood collection system in Europe. The Cymbal system is a portable device for collecting two units of red blood cells from a single blood donor in one donation.
IRIS International, Inc. acquired molecular diagnostics company Leucadia Technologies for $10.1 million. Leucadia will become part of the new into a new Iris Molecular Diagnostics. Leucadia developed the Nucleic Acid Detection ImmunoAssay (NADIA) and a bubble isolation technology that enables rapid separation and concentration of rare cells in blood and urine.
Siemens and Diagnostic Products Corporation (DPC) announced that they have entered into a merger agreement under which Siemens will acquire DPC for approximately $1.86 billion.
ViaCell, Inc. and Pall Corporation received FDA clearance to market a cord blood collection bag suitable for use in a sterile field. ViaCell has exclusive rights to the new collection bag for family cord blood banking and expects to introduce it as part of its ViaCord collection kit.
![[Page Banner Image]](images/hprods.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
